Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in  non-small cell lung cancer

CONCLUSION: Compared with rhG-CSF, mecapegfilgrastim is not a cost-effective strategy for NSCLC patients in neutropenia prevention in China.PMID:38263810 | DOI:10.5414/CP204479

Source: International Journal of Clinical Pharmacology and Therapeutics - January 24, 2024 Category: Drugs & Pharmacology Authors: Yong-Li Gu Zeng-Xian Sun Ying Sun Xin Guan Dao-Li Jiang Source Type: research